The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Duvelisib receives Orphan Drug designation from the FDA for the treatment of T-cell lymphoma
On the 3rd of October 2019 the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for duvelisib as a treatment for patients with T-cell lymphoma in addition to the previously-granted Fast Track status, for peripheral T-Cell lymphoma.1
Duvelisib, is an oral inhibitor of phosphoinositide 3-kinase (PI3K)-δ and PI3K-γ, enzymes involved in pathways supporting the growth and survival of malignant B-cells, as well as the formation and maintenance of the tumor microenvironment.
The drug has been previously approved for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and accelerated approval in follicular lymphoma (FL) after at least two prior systemic therapies. The phase II PRIMO study of duvelisib monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) is currently ongoing and will provide further data on dosing regimen, efficacy and safety.
References